Insulin Lispro vs THDB0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin Lispro · Humalog

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01474538 · Phase 3 · completed

The study randomized 122 participants to receive both insulin lispro and insulin aspart in crossover order, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint, HbA1c after 16 weeks, met the prespecified non-inferiority criterion for lispro versus aspart, with the upper confidence limit below the 0.4% margin.

Next expected readout: December 2026 · NCT06251635 (registry estimate)

Reported efficacy

Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Insulin Lispro 7.5 percentage of glycosylated hemoglobin (Standard Error 0.12) | Insulin Aspart 7.4 percentage of glycosylated hemoglobin (Standard Error 0.12) (met)

Result source: NCT01474538

THDB0206

Developed by Adocia and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05834868 · Phase 3 · completed

The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin LisproTHDB0206
HbA1c, change-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
—Not posted · NCT05834868
Body weight, change (kg)-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
—Not posted · NCT05834868
HbA1c below 7%32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
—Not posted · NCT05834868
Fasting plasma glucose, change-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
—Not posted · NCT05834868
3-point MACE (% with event)—Not posted · NCT00551356—Not posted · NCT05834868

HbA1c, change

Insulin Lispro
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
THDB0206
—Not posted · NCT05834868

Body weight, change (kg)

Insulin Lispro
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
THDB0206
—Not posted · NCT05834868

HbA1c below 7%

Insulin Lispro
32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
THDB0206
—Not posted · NCT05834868

Fasting plasma glucose, change

Insulin Lispro
-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
THDB0206
—Not posted · NCT05834868

3-point MACE (% with event)

Insulin Lispro
—Not posted · NCT00551356
THDB0206
—Not posted · NCT05834868
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDB0206: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin Lispro: 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin Lispro
Dropout rate
—a
NCT01474538 · Phase 3
show 18 more results
19.3%
NCT00664534 · Phase 4 · registry result, not featured evidence
15.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
12.7%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
10.3%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
19.7%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
18.8%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
9.6%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
11.1%
NCT05893797 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01474538 · Phase 3
show 18 more results
1.8%
NCT00664534 · Phase 4 · registry result, not featured evidence
0%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
3.5%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
1.7%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
7.1%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.4%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0.5%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
2.8%
NCT05893797 · Phase na · registry result, not featured evidence
Serious AEs
12.7%a
NCT01474538 · Phase 3
show 18 more results
4.1%
NCT00664534 · Phase 4 · registry result, not featured evidence
2.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.8%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
21.4%1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
25.3%0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
11.4%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
9.2%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
15.7%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.8%Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
7.5%Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0%Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
4.5%Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
0%Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
0%
NCT02197520 · Phase 1 · registry result, not featured evidence
8.3%
NCT05893797 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 4.2%
nausea 4.2%
fatigue 3.4%
NCT01474538 · Phase 3
show 17 more results
pyrexia 3.6%
neuropathy peripheral 3%
diarrhoea 2.4%
NCT00664534 · Phase 4 · registry result, not featured evidence
nasopharyngitis 4.3%
bronchitis 2.2%
arthralgia 1.4%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 9.3%
diarrhoea 7.8%
viral upper respiratory tract infection 6.3%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3 · registry result, not featured evidence
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.1%
upper respiratory tract infection 4.2%
diarrhoea 3.5%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
nausea 25.8%
diarrhea 14.9%
vomiting 11.9%
NCT01191268 · Phase 3 · registry result, not featured evidence
0.75 mg
nausea 17.7%
diarrhea 11.6%
vomiting 10.6%
NCT01191268 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.4%
headache 5.9%
diarrhoea 4.3%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 5.3%
headache 4.8%
viral infection 3.7%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
headache 3.4%
influenza 3.4%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
abdominal pain 4.5%
diarrhoea 4.5%
injection site pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
headache 13.6%
nausea 9.1%
abdominal pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
catheter site related reaction 12.5%
upper respiratory tract infection 12.5%
urinary tract infection 12.5%
NCT02197520 · Phase 1 · registry result, not featured evidence
covid-19 8.3%
bronchitis 5.6%
dermatitis allergic 5.6%
NCT05893797 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 18 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin Lispro

HbA1c 7.5% (n=112) vs 7.4% (n=111) Insulin Aspart @ 16wk
absolute value · percentage points
NCT01474538 · Phase 3
show 6 more results
7.4% (n=108) vs 7.55% (n=98) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.62% (n=158) vs 7.57% (n=163) Glargine @ 16wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.46% (n=158) vs 7.43% (n=163) Glargine @ 32wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.33% (n=158) vs 7.4% (n=163) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.71% (n=131) vs 7.84% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.76% (n=684) vs 6.97% (n=672) Insulin Glargine + Insulin Lispro @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
Weight -2.81 vs 1.11 Insulin Glargine kg @ 26wk1.5 mg
absolute change · kg
NCT01621178 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.66 vs 1.57 Insulin Glargine kg @ 52wk1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-2.02 vs 1.11 Insulin Glargine kg @ 26wk0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-1.71 vs 1.57 Insulin Glargine kg @ 52wk0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
0.31 vs 0.89 Insulin Aspart kg @ 16wk
NCT01474538 · Phase 3
2.61 vs 2.7 Glargine kg @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
1.3 vs 0.4 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM kg @ 16wk
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
2.67 vs 2.53 Insulin Glargine kg @ 26wk
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.95 vs 2.43 Insulin Lispro + Insulin Glargine kg @ 26wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.55 vs 0.66 Insulin Lispro + Insulin Glargine kg @ 4wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.95 vs 0.85 Insulin Lispro + Insulin Glargine kg @ 5wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.71 vs 1.46 Insulin Lispro + Insulin Glargine kg @ 10wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.96 vs 2.06 Insulin Lispro + Insulin Glargine kg @ 18wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.95 vs 2.43 Insulin Lispro + Insulin Glargine kg @ 26wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.25 vs 2.21 Insulin Glargine + Insulin Lispro kg @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.03 vs 1.19 Glargine kg @ 24wk
NCT00666718 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 30.3% (n=158) vs 24.2% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=7.0% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 18.7% (n=158) vs 14.6% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=6.5% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 37.6% (n=158) vs 32.1% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=7.0% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 20.6% (n=158) vs 19% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=6.5% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 48.2% (n=158) vs 36.2% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=7.0% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 24.8% (n=158) vs 18.5% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=6.5% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 21.4% (n=131) vs 18.5% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c <7%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
A1C Less Than 6 5 11.5% (n=131) vs 6.7% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c ≤6.5%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
HbA1c -1.19% (n=138) vs -1.13% (n=175) Insulin Glargine @ 26wk1.5 mg
absolute change · percentage points
NCT01621178 · Phase 3 · registry result, not featured evidence
show 20 more results
-1.1% (n=130) vs -1% (n=153) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-1.64% (n=273) vs -1.41% (n=276) Insulin Glargine @ 26wk1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
-1.48% (n=273) vs -1.23% (n=276) Insulin Glargine @ 52wk1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
-1.12% (n=149) vs -1.13% (n=175) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-1.1% (n=132) vs -1% (n=153) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-1.59% (n=275) vs -1.41% (n=276) Insulin Glargine @ 26wk0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
-1.42% (n=275) vs -1.23% (n=276) Insulin Glargine @ 52wk0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
-1% (n=131) vs -0.82% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
-1.01% (n=361) vs -1% (n=362) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.01% (n=361) vs -1% (n=362) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.04% (n=345) vs -1.1% (n=350) Insulin Lispro + Insulin Glargine @ 26wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.59% (n=402) vs -0.47% (n=412) Insulin Lispro + Insulin Glargine @ 4wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.67% (n=402) vs -0.58% (n=412) Insulin Lispro + Insulin Glargine @ 5wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.88% (n=402) vs -0.96% (n=412) Insulin Lispro + Insulin Glargine @ 10wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.04% (n=402) vs -1.14% (n=412) Insulin Lispro + Insulin Glargine @ 18wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.04% (n=402) vs -1.1% (n=412) Insulin Lispro + Insulin Glargine @ 26wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.66% (n=684) vs -1.45% (n=672) Insulin Glargine + Insulin Lispro @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
-1.18% (n=148) vs -1.28% (n=163) Glargine @ 24wk
NCT00666718 · Phase 3 · registry result, not featured evidence
-0.9% (n=179) vs -0.99% (n=180) Glargine @ 12wk
NCT00666718 · Phase 3 · registry result, not featured evidence
-1.07% (n=179) vs -1.29% (n=180) Glargine @ 24wk
NCT00666718 · Phase 3 · registry result, not featured evidence
PP 2 h Glucose mg/dL 163.4 vs 178.2 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination

+ 50 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Lispro's landscape · THDB0206's landscape